Vir Biotechnology, Inc. informally revealed that it had around $1.9 billion in cash, cash equivalents, and investments as of June 30, 2023. The company also announced that their Phase 2 PENINSULA trial for prevention of influenza A did not meet the primary or secondary efficacy endpoints, indicating a reduction of only about 16% in influenza A.